SINUS WASH Pilot Study in Adults Testing Positive for COVID-19
Primary Purpose
Coronavirus Infection
Status
Unknown status
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
Povidone-Iodine
Normal saline
Sponsored by
About this trial
This is an interventional treatment trial for Coronavirus Infection focused on measuring COVID-19, sinus rinse, mouth wash, povidone-iodine, coronavirus, Wuhan
Eligibility Criteria
Inclusion Criteria:
- Healthcare worker OR patient on a general ward who has had a positive COVID-19 test OR a person who is co-residing with an affected staff member or patient who is now at home in self-isolation.
- capable of giving informed consent
- able to self-administer the sinus rinses and mouth washes
- able to have healthcare professional-led swabs OR self-administer the oral and nasopharyngeal swabs
- aged 18 years and over.
Exclusion Criteria:
- not capable of giving informed consent
- unable to self-administer the sinus rinses and mouth washes
- unable to have healthcare professional-led swabs OR self-administer the oral, nasal and/OR nasopharyngeal swabs
- unable to send swabs to the study team via the approved methods described in participant information leaflet and protocol
- under 18 years of age.
- known hypersensitivity to Iodine
- at risk of aspiration due to an unsafe swallow
- hyperthyroidism or other manifest thyroid diseases
- herpetiform dermatitis (Duhring's disease)
- planned or undergoing radioiodine treatment
- actively Breastfeeding
- pregnant
Sites / Locations
- Hampshire Hospitals NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Povidone-Iodine
Normal Saline
Arm Description
0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
Outcomes
Primary Outcome Measures
Change in viral load in the oral and nasopharyngeal cavity
viral load as measured by real time polymerase chain reaction (PCR)
Secondary Outcome Measures
Symptom severity in primary participants and co-residents
Visual analogue score 1-5 per symptom via a smartphone app
Full Information
NCT ID
NCT04393792
First Posted
May 18, 2020
Last Updated
September 16, 2021
Sponsor
Hampshire Hospitals NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT04393792
Brief Title
SINUS WASH Pilot Study in Adults Testing Positive for COVID-19
Official Title
Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 5, 2020 (Actual)
Primary Completion Date
March 2022 (Anticipated)
Study Completion Date
March 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hampshire Hospitals NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.
Detailed Description
COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that reaches other parts of the body. This also could mean that there is less virus available to pass on to others.
We want to see if the use of nasal rinsing and mouth washes will reduce the spread of infection within your household by reducing and removing the virus from your mouth and nose.
Once the participants have been recruited they will be randomly allocated to one of two groups. Each arm will have the same number of participants. The two arms will be :
nose rinse and mouthwash with Isotonic saline alone. This will be the control arm.
nose rinse and mouthwash with Povidone-Iodine taken 3 times a days for three days.
Before treatment begins, each participant will have one pre-treatment swab of the back of the nose and the back of the throat taken.
Once allocated each participant will be asked to have 4 further swabs of the mouth and nose taken on days 2,4,7 & 14.
Participants will be patients and healthcare staff who have tested positive for COVID-19. Healthcare staff who are self isolating will also asked their co-residents/family members at home to take the treatment and provide swabs in the same manner.
Participants who are patients and are admitted to hospital will be well enough to perform the nasal rinses and mouth washes as treatments and provide the same swabs.
All participants will be provided with informational videos on how to do the treatments and how to take the swabs. Participants who are not healthcare staff will have swabs taken as part of the local drive through testing service.
All participants will be asked to download a free smartphone app (Umotif) to upload information about daily symptoms and whether they have provided swabs on the required days.
The swabs will be tested for the amount of virus in the labs at Hampshire Hospitals NHS Foundation Trust and analysed to determine if the treatment arm of Povidone-Iodine is reducing the amount of virus compared to the isotonic saline arm.
All results will be anonymised prior to analysis. The study team will know the participants' study-specific data; no personal data about participants will be used without their explicit consent and only for the purposes of protocol adherence and data to answer the study question.
Once the last swab has been taken and delivered to the laboratory, the trial will have ended for that participant. Results of the swabs will be part of the study data and collated in readiness for analysis by the study statistician.
The results will be made available for peer-reviewed publication and presentation at conferences.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronavirus Infection
Keywords
COVID-19, sinus rinse, mouth wash, povidone-iodine, coronavirus, Wuhan
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
unblinded parallel group design with 1:1 randomised allocation to treatment or control
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Povidone-Iodine
Arm Type
Active Comparator
Arm Description
0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
Arm Title
Normal Saline
Arm Type
Placebo Comparator
Arm Description
sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
Intervention Type
Drug
Intervention Name(s)
Povidone-Iodine
Other Intervention Name(s)
Videne Antiseptic Solution
Intervention Description
0.23% three times daily (tds) for 3 days
Intervention Type
Drug
Intervention Name(s)
Normal saline
Intervention Description
0.9% three times daily (tds) for 3 days
Primary Outcome Measure Information:
Title
Change in viral load in the oral and nasopharyngeal cavity
Description
viral load as measured by real time polymerase chain reaction (PCR)
Time Frame
Day 0, 2, 3, 7, 14
Secondary Outcome Measure Information:
Title
Symptom severity in primary participants and co-residents
Description
Visual analogue score 1-5 per symptom via a smartphone app
Time Frame
Days 0 to 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Healthcare worker OR patient on a general ward who has had a positive COVID-19 test OR a person who is co-residing with an affected staff member or patient who is now at home in self-isolation.
capable of giving informed consent
able to self-administer the sinus rinses and mouth washes
able to have healthcare professional-led swabs OR self-administer the oral and nasopharyngeal swabs
aged 18 years and over.
Exclusion Criteria:
not capable of giving informed consent
unable to self-administer the sinus rinses and mouth washes
unable to have healthcare professional-led swabs OR self-administer the oral, nasal and/OR nasopharyngeal swabs
unable to send swabs to the study team via the approved methods described in participant information leaflet and protocol
under 18 years of age.
known hypersensitivity to Iodine
at risk of aspiration due to an unsafe swallow
hyperthyroidism or other manifest thyroid diseases
herpetiform dermatitis (Duhring's disease)
planned or undergoing radioiodine treatment
actively Breastfeeding
pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Afroze Khan, MBBS MRCS
Phone
+447885903693
Email
Afroze.Khan@nhs.net
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew Dryden
Email
matthew.dryden@hhft.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Afroze Khan, MBBS MRCS
Organizational Affiliation
Hampshire Hospitals NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hampshire Hospitals NHS Foundation Trust
City
Basingstoke
State/Province
Hampshire
ZIP/Postal Code
RG24 9NA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Afroze Khan, MBBS MRCS
First Name & Middle Initial & Last Name & Degree
Matthew Dryden
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
SINUS WASH Pilot Study in Adults Testing Positive for COVID-19
We'll reach out to this number within 24 hrs